UY32849A - Inhibidores heteroarilicos biciclicos de pde4 - Google Patents

Inhibidores heteroarilicos biciclicos de pde4

Info

Publication number
UY32849A
UY32849A UY0001032849A UY32849A UY32849A UY 32849 A UY32849 A UY 32849A UY 0001032849 A UY0001032849 A UY 0001032849A UY 32849 A UY32849 A UY 32849A UY 32849 A UY32849 A UY 32849A
Authority
UY
Uruguay
Prior art keywords
pde4
inhibitors
heteroarilic
bicycle
diseases
Prior art date
Application number
UY0001032849A
Other languages
English (en)
Inventor
Mark R Hellberg
Beauregard Clay
Steven P Govek
Daniel A Gamache
Stewart A Noble
Andrew K Shiau
David J Thomas
John M Yanni
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of UY32849A publication Critical patent/UY32849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención se refiere a compuestos y métodos que pueden ser útiles como inhibidores de f osfodiesterasa 4 (PDE4) . para el tratamiento o la prevención de enfermedades inflamatorias y otras enfermedades que incluyen niveles elevados de citoquinas y mediadores pro inflamatorios.
UY0001032849A 2009-08-19 2010-08-19 Inhibidores heteroarilicos biciclicos de pde4 UY32849A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/544,185 US8138205B2 (en) 2006-07-07 2009-08-19 Heteroarylalkoxy-substituted quinolone inhibitors of PDE4

Publications (1)

Publication Number Publication Date
UY32849A true UY32849A (es) 2011-03-31

Family

ID=43989737

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032849A UY32849A (es) 2009-08-19 2010-08-19 Inhibidores heteroarilicos biciclicos de pde4

Country Status (14)

Country Link
US (2) US8138205B2 (es)
EP (1) EP2467376A4 (es)
JP (1) JP2013502432A (es)
KR (1) KR20120051071A (es)
CN (1) CN102686578A (es)
AR (1) AR078142A1 (es)
AU (1) AU2010344165A1 (es)
BR (1) BR112012003738A2 (es)
CA (1) CA2770767A1 (es)
CO (1) CO6612202A2 (es)
MX (1) MX2012001695A (es)
TW (1) TW201111363A (es)
UY (1) UY32849A (es)
WO (1) WO2011093924A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
AU2007269070B2 (en) * 2006-07-07 2013-03-21 Steven P. Govek Bicyclic heteroaryl inhibitors of PDE4
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
CN106795165B (zh) 2014-08-06 2019-09-10 辉瑞公司 咪唑并哒嗪化合物
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN106916104B (zh) * 2017-02-28 2019-08-27 牡丹江医学院 用于治疗结肠炎的药物
CN117187343A (zh) * 2023-09-06 2023-12-08 青岛大学 一种磷酸二酯酶抑制剂的高通量筛选方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
CA2091172C (en) 1990-09-07 1997-05-20 Adriano Afonso Antiviral compounds and antihypertensive compounds
WO1992017452A1 (en) 1991-04-03 1992-10-15 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives
US5412401A (en) * 1991-04-12 1995-05-02 Abekas Video Systems, Inc. Digital video effects generator
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
DE60327750D1 (de) * 2002-03-18 2009-07-09 Merck Frosst Canada Ltd Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin
WO2004018419A2 (en) 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
PE20060241A1 (es) * 2004-05-18 2006-04-01 Schering Corp 2-quinolil-oxazoles sustituidos como inhibidores de pde4
KR101331786B1 (ko) 2004-09-22 2013-11-21 얀센 파마슈티카 엔.브이. Ｍｄｍ2 및 ｐ53간의 상호작용 저해제
US8048889B2 (en) 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
DK1928457T3 (da) 2005-09-30 2013-02-04 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
AU2007269070B2 (en) * 2006-07-07 2013-03-21 Steven P. Govek Bicyclic heteroaryl inhibitors of PDE4

Also Published As

Publication number Publication date
JP2013502432A (ja) 2013-01-24
AU2010344165A1 (en) 2012-03-01
TW201111363A (en) 2011-04-01
CA2770767A1 (en) 2011-08-04
CN102686578A (zh) 2012-09-19
AR078142A1 (es) 2011-10-19
CO6612202A2 (es) 2013-02-01
KR20120051071A (ko) 2012-05-21
WO2011093924A1 (en) 2011-08-04
US20100081646A1 (en) 2010-04-01
EP2467376A1 (en) 2012-06-27
EP2467376A4 (en) 2013-01-16
BR112012003738A2 (pt) 2019-09-24
US20130045975A1 (en) 2013-02-21
MX2012001695A (es) 2012-07-23
US8138205B2 (en) 2012-03-20

Similar Documents

Publication Publication Date Title
UY32849A (es) Inhibidores heteroarilicos biciclicos de pde4
UY32110A (es) Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
UY32111A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
TR201901886T4 (tr) DNA-PK inhibitörleri.
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
MX2009000148A (es) Inhibidores heteroaril biciclicos de fosfodiesterasa 4.
MX368959B (es) Inhibidores heteroarilo de pde4.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CR20110560A (es) Métodos de tratamiento para tumores sólidos
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
ES2525801T8 (es) Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
EA201101477A1 (ru) Органические соединения и их применение
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
ECSP13012824A (es) Derivados de (1,2,4)triazolo[4,3-a)quinoxalina como inhibidores de fosfodiesterasas
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127